RBC Capital on Legend Biotech Corp. (LEGN): 'See An Attractive Entrypoint With Strong 2025 Growth Potential'
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $84.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
